Pharma8k's (Page 4)

Enliven Therapeutics (ELVN) Appoints Rick Fair as CEO, Plans 2026 Phase 3 Trial for CML Drug

11 Dec 2025 SEC Filing 8-K $ELVN

Enliven Therapeutics (ELVN) Appoints Rick Fair as CEO, Plans 2026 Phase 3 Trial for CML Drug

Enliven Therapeutics (ELVN) appointed Rick Fair as CEO with a $660,000 base salary and plans a pivotal Phase 3 trial for ELVN-001 in chronic myeloid leukemia in 2026.

Climb Bio (CLYM) Exchanges 20.4 Million Shares for Pre-Funded Warrants with RA Capital

11 Dec 2025 SEC Filing 8-K M&A $CLYM

Climb Bio (CLYM) Exchanges 20.4 Million Shares for Pre-Funded Warrants with RA Capital

Climb Bio, Inc. (CLYM) exchanged 20.4 million shares of common stock for pre-funded warrants in a deal with RA Capital Management.

Cadrenal Therapeutics (CVKD) Acquires VLX-1005 for HIT, Bolsters Pipeline with $3.9M Cash

11 Dec 2025 SEC Filing 8-K $CVKD

Cadrenal Therapeutics (CVKD) Acquires VLX-1005 for HIT, Bolsters Pipeline with $3.9M Cash

Cadrenal Therapeutics (CVKD) acquired VLX-1005 for HIT from Veralox for $200,000, with $3.9M cash on hand as of Sept 2025.

Climb Bio (CLYM) Exchanges 20.4 Million Shares for Pre-Funded Warrants with RA Capital

11 Dec 2025 SEC Filing 8-K M&A $CLYM

Climb Bio (CLYM) Exchanges 20.4 Million Shares for Pre-Funded Warrants with RA Capital

Climb Bio (CLYM) exchanged 20.4 million shares for pre-funded warrants with RA Capital Management, per an SEC 8-K filing.

TransCode Therapeutics (RNAZ) Launches Phase 2a Trial for Colorectal Cancer Drug TTX-MC138

11 Dec 2025 SEC Filing 8-K Clinical Trials $RNAZ

TransCode Therapeutics (RNAZ) Launches Phase 2a Trial for Colorectal Cancer Drug TTX-MC138

TransCode Therapeutics (RNAZ) filed an 8-K on Dec 11, 2025, announcing a Phase 2a dose-expansion trial for TTX-MC138 in colorectal cancer with minimal residual disease.